ÌÇÄò²¡×÷ΪһÖÖÂýÐÔ´úлÐÔ¼²²¡£¬Í¨³£²»»áÔÚ»¼ÕßÉíÉÏ×ÔÁ¦±£´æ£¬¶ø³£ÓëÆäËûÖî¶à·Ç¿µ½¡×´Ì¬»ò¼²²¡²¢´æ£¬ÔÚÕâ¸öÊý²¡Æë·¢µÄÀú³ÌÖÐÌÇÄò²¡ÍùÍùÊÇ¡°¿ªÂ·Ïȷ桱£¬¾Ýͳ¼ÆÈ«Çò¸ß´ï4ÒÚ¶àÈ˱¥ÊÜÌÇÄò²¡À§ÈÅ£¬ÆäÖÐÎÒ¹úÌÇÄò²¡»¼²¡ÈËÊý¾ÓÈ«ÇòÖ®Ê×£¬Òѳ¬1.3 ÒÚ¡£ÎªÏàʶ¾öÌÇÄò²¡Õâ¸ö¡°ÌðÃۼ縺¡±£¬ÎÒÃÇÐèҪ̽ÌÖÌÇÄò²¡µÄ·¢²¡»úÖÆ£¬Õë¶ÔÿһÀàÌÇÄò²¡¹¹½¨ºÏÊʵĶ¯ÎïÄ£×Ó£¬¿ª·¢¶ÔÖ¢µÄÒ©Îï¡£½ñÌ죬С±à¾ÍΪ¸÷ÈËÏÈÈÝÒ»ÏÂÌÇÄò²¡Ñо¿³£ÓõÄÄ£×Ó¡£
ͼ1.È«ÇòÌÇÄò²¡»¼Õßͳ¼Æ
ÌÇÄò²¡ÊÇÒÔ¸ßѪÌÇΪÌØÕ÷µÄÂýÐÔ´úлÐÔ¼²²¡£¬ÇÒÄÑÒÔÖÎÓúÒ»Ñùƽ³£ÐèÒªÖÕÉú·þÒ©¡£ÌÇÄò²¡µÄ¿Ö²ÀÔÚÓÚÆä»áµ¼ÖÂÑÛ¡¢Éö¡¢ÐÄÔࡢѪ¹Ü¡¢Éñ¾µÈ×éÖ¯Æ÷¹ÙµÄÂýÐÔËðÉ˺͹¦Ð§ÕÏ°£¬²¢ÓиÅÂÊÒýÆðÖݪֲ¢·¢Ö¢£¬ÈçʧÃ÷¡¢ÉöË¥½ß¡¢ÐÄÔಡ¡¢ÖзçºÍÏÂÖ«½Ø̱µÈ¡£¾Ý¡¶Öйú2ÐÍÌÇÄò²¡·ÀÖÎÖ¸ÄÏ£¨2020°æ£©¡·Ö¸³ö£¬ÎÒ¹úÌÇÄò²¡»¼²¡ÂÊÒÑÉÏÉýÖÁ11.2%£¬Ò²¾ÍÊÇ˵ÎÒ¹úÿ10¸ö³ÉÄêÈ˾ÍÓÐ1¸öÌÇÄò²¡»¼Õߣ¬Õâ¶ÔСÎÒ˽¼ÒºÍÉç»á¶¼ÊǼ«Öصļ縺[1]¡£
ͼ2.ÌÇÄò²¡²¢·¢Ö¢
ÁÙ´²ÉϹØÓÚÌÇÄò²¡µÄ²¡Òò·ÖÐÍ£¬ÏÖÔÚÓ¦ÓÃ×îΪÆձ顢¸ÅÂÔÉÏ×î±»¹«ÈÏÊÇ1999ÄêÌìÏÂÎÀÉú×éÖ¯£¨WHO£©Ðû²¼µÄÕâ4À࣬¼´1ÐÍÌÇÄò²¡£¨T1DM£©¡¢2ÐÍÌÇÄò²¡£¨T2DM£©¡¢ÌØÊâÀàÐÍÌÇÄò²¡ºÍÈÑÉïÆÚÌÇÄò²¡£¨GDM£©¡£2019ÄêWHOÓÖÔÚ´Ë»ù´¡ÉÏ£¬½«³ÉÈËÒþÄäÐÔ×ÔÉíÃâÒßÌÇÄò²¡£¨LADA£©ºÍ֢ͪÇãÏòT2DM¹éÀàΪ¡°»ìÏýÐÍÌÇÄò²¡¡±£¬ÇÒÌí¼ÓÁË¡°Î´·ÖÀàÌÇÄò²¡¡±£¬´Ó¶ø½«ÌÇÄò²¡·ÖΪ6ÖÖÀàÐÍ[5]¡£Ã¿ÖÖÀàÐÍÌÇÄò²¡µÄÌØÕ÷ÈçÏ£º
T2DMÊÇÌÇÄò²¡»¼ÕßÖÐ×îÖ÷ÒªµÄȺÌ壬ÆäÖ÷Òª·¢²¡Ôµ¹ÊÔÓÉÊÇÒȵºËضԿ¹¼°ÒȵºËØÉø͸Ïà¶Ôȱ·¦¡£
T1DMÊÇÓÉÓÚÒȵº¦Âϸ°ûÆÆËð¡¢ÒȵºËØÉø͸ȱ·¦ËùÖ£¬ÌØÕ÷ÊÇÒȵº¹¦Ð§²î£¬ÖÕÉíÐèÒªÒÀÀµÒȵºËØÖÎÁÆ¡£
¼Ì·¢ÐÔÌÇÄò²¡ÊÇÒ»ÀàÓÉÌض¨¼²²¡»òÒ©ÎïµÈÏà¹ØÒòËØÒýÆðѪÌÇÉý¸ßµÄÌÇÄò²¡ÀàÐÍ¡£
GDMÊÇÖ¸ÓëÈÑÉï״̬Ïà¹ØµÄÌÇ´úлÒì³££¬µ«Î´µÖ´ï·ÇÔÐÈËȺÌÇÄò²¡Õï¶Ï±ê×¼£¬GDM»¼ÕßÌÇ´úл´ó¶¼ÓÚ²úºóÄָܻ´Õý³££¬µ«Î´À´»¼IIÐÍÌÇÄò²¡¸ÅÂÊÒ²»áÔöÌí¡£
µ¥»ùÒòÌÇÄò²¡ÓÉÓ°ÏìÒȵº¦Âϸ°û·¢Óý¡¢¹¦Ð§»òÒȵºËØ×÷Óõĵ¥¸ö»ùÒòÍ»±äËùÖ£¬Ô¼Õ¼ËùÓÐÌÇÄò²¡µÄ1%~5%£¬Æù½ñÒÑ·¢Ã÷70Óà¸öµ¥»ùÒòÌÇÄò²¡µÄÖ²¡»ùÒò£¬´ó´ó¶¼Í¨¹ýÓ°ÏìÒȵº¦Âϸ°û¹¦Ð§¶øÖÂѪÌÇÒì³£¡£
䶨ÐÍÌÇÄò²¡Ö¸²¿·ÖÌÇÄò²¡»¼ÕßÌåÏÖ²»µä·¶£¬Æ¾Ö¤ÆäÖ¢×´¡¢ÌåÕ÷ºÍÒѾÍê³ÉÇ°ÊöµÄÒȵº¹¦Ð§¡¢Òȵº×ÔÉí¿¹Ìå¼°»ùÒò¼ì²âµÈЧ¹ûÈÔ²»¿É·ÖÐÍÕß¡£
ÏÖÔÚ£¬ÊÐÃæÉÏÒÑÓжà¿îÖÎÁƲî±ðÌÇÄò²¡µÄÒ©ÎÕâЩҩÎïÓÐÓøÄÉÆÁËÖÚ¶àÌÇÄò²¡»¼ÕßµÄÉúÑÄÖÊÁ¿£¬µ«ÏÖÓеÄÖÎÁÆÕ½ÂÔÎÞ·¨×èÖ¹ÌÇÄò²¡µÄÏ£ÍûºÍÂýÐÔ²¢·¢Ö¢µÄ±¬·¢£¬ÇҴ󲿷ÖÒ©ÎïÕë¶ÔµÄ¶¼ÊÇ×î³£¼ûµÄT2DMºÍT1DM£¬ÆäËûÀàÐ͵ÄÌÇÄò²¡ÈËȱ·¦×ã¹»µÄÖÎÁÆÊֶΡ£Òò´Ë£¬ÌÇÄò²¡µÄÑо¿ÒÀÈ»ÈÎÖصÀÔ¶¡£
ÌÇÄò²¡ÊµÑ鶯ÎïÄ£×Ó×÷ΪÖ÷ÒªµÄ¿ÆÑй¤¾ß£¬ÔÚÌÇÄò²¡»úÀíÑо¿£¬Ò©ÎïɸѡÒÔ¼°Ò©ÎïÁÙ´²Ç°ÊµÑ鶼ʩչÁËÖ÷Òª×÷Óá£ÏÖÔÚ£¬Ëæ×ÅÉúÎïҽѧÊÖÒÕµÄһֱǰ½ø£¬ÌÇÄò²¡¶¯ÎïÄ£×ÓÔìÄ£ËùÓõÄʵÑ鶯ÎïÖÖÀàºÍÔìÄ£ÊÖ¶ÎÈճʶàÔª»¯Éú³¤£¬ÌÇÄò²¡¶¯ÎïÄ£×ӵĹ¹½¨Ò²ÄܸüºÃµØÄ£ÄâÈËÀàÌÇÄò²¡µÄ±¬·¢Éú³¤¡£Õë¶Ô²î±ðÒòËص¼ÖµÄÌÇÄò²¡£¬Ñо¿Ö°Ô±Ó¦Ñ¡ÔñÓëÖ®Ñо¿Ö÷ÌåÏà¿¿½üµÄÌÇÄò²¡Ä£×Ó×÷ΪÑо¿¹¤¾ß¡£Ð¡±àÔڴ˹éÄÉ×ܽáÁËÄ¿½ñÌÇÄò²¡Ñо¿µÄÖ÷ÒªÄö³ÝÀàÄ£×Ó£¬ÒÔ÷϶ÁÕß¡£
ͼ3.СÊóÄ£×Ó
2.1 ×Ô¾õÐÔÌÇÄò²¡Ä£×Ó
×Ô¾õÐÔÌÇÄò²¡¶¯ÎïÄ£×ÓÊÇÖ¸ÔÚ×ÔÈ»Ìõ¼þÏ£¬Î´¾ÓÉÈ˹¤´¦Öóͷ£¶ø±¬·¢ÌÇÄò²¡µÄʵÑ鶯ÎÇÒÆä×ÓÅ®ÈÔ»òÐíÂÊ»¼ÌÇÄò²¡¡£³£¼ûµÄ×Ô¾õÐÔÌÇÄò²¡ÓÐNODСÊó¡¢ob/obСÊó¡¢db/dbСÊó¡¢BB´óÊó¡¢LETL´óÊóµÈ¡£×Ô¾õÐÔÄ£×Ó¶¯ÎïÌÇÄò²¡µÄ±¬·¢Éú³¤Àú³ÌÓëÈËÀàµÄÌÇÄò²¡ÏàËÆ£¬ÔÚÌÇÄò²¡Ñо¿ÉÏÓ¦ÓÃÆձ飬³£ÓÃ×Ô¾õÐÔÌÇÄò²¡¾ÞϸÊóÄ£×ÓÈçϱíËùʾ¡£
»¯Ñ§Ò©ÎïÓÕµ¼£ºÒÑ·¢Ã÷¶àÖÖ»¯ºÏÎï¿ÉÔÚ¶¯ÎïÄ£×ÓÓÕ·¢ÌÇÄò²¡£¬ÆäÖÐÁ´ëå×ô¾úËØ(Streptozotocin,STZ)ºÍËÄÑõà×à¤(Alloxan,ALX)ÊÇ×î³£Óõģ¬ÕâÁ½ÖÖÒ©ÎﶼÊÇϸ°û¶¾ÐÔÆÏÌÑÌÇÀàËÆÎ¶ÔGLUT2תÔËÌå¾ßÓи߶ÈÇ׺ÍÁ¦£¬Ö÷ÒªÆÆËðÒȵº¦Âϸ°û[2]¡£±ÈÆðALX£¬STXÒòÆä¾ßÓиüºÃµÄÎȹÌÐԺ͸üСµÄ¶¾ÐÔ¶ø¸üÊܽӴý¡£ÈôÔÚ¾ÞϸÊóÓÐÉíʱ´ú£¬¾ÙÐÐSTZÓÕµ¼Ôò¿ÉÒÔ¹¹½¨GDMÄ£×Ó¡£µ«ÕâÖÖÒªÁì±£´æÒ»¶¨µÄΣº¦£¬¿ÉÄܵ¼ÖÂÔÐÊóÁ÷²ú£¬ÇÒSTZ¶ÔÒȵºµÄÆÆËðÊDz»¿ÉÄæµÄ£¬¶øÒ»Ñùƽ³£GDM»¼ÕßѪÌÇÔÚ²úºóÄָܻ´Õý³££¬Òò´ËʵÑ鶯Îï¿ÉÒÔÔÚ²úºóÔÙÒÆÖ²Ò»¸öÕý³£µÄÒȵº£¬¿ÉÊÇÕâ¸öÊÖÊõÄѶȸßÇÒ±¾Ç®²»·Æ¡£
ͼ4.STZÆÆËðÒȵº¦Âϸ°ûÔÀíͼ[6]
ÒûʳÓÕµ¼£¨DIO£©£ºÒûʳÓÕµ¼µÄ¶¯ÎïÌÇÄò²¡Ä£×ÓÓëÈËÀàÌÇÄò²¡ÏàËÆ£¬³£ÓÃÀ´Ñо¿Òûʳ¡¢»ùÒòµÈÒòËØÓë·ÊÅÖ/ÌÇÄò²¡µÈ¼²²¡Àú³ÌÖ®¼äµÄ¹Øϵ¡£ÀýÈçC57BL/6СÊóÒ»Á¬¸ßÖ¬ÒûʳËÇι14ÖÜ×óÓÒ£¬¼ì²âÌÇÄò²¡Ïà¹ØÖ¸±ê£¬ÕâÀàÄ£×Ó¿ÉÓÃÓÚ·ÊÅÖ¡¢IIÐÍÌÇÄò²¡Ñо¿¡£
ͼ5.DIO·ÊÅÖСÊó
ÊÖÊõÓÕµ¼£ºÖ±½ÓËùÓлò´ó²¿·ÖÇгýʵÑ鶯ÎïµÄÒÈÏÙ£¬ÈôÊÇÒ»Á¬Á½ÌìѪÌÇÖµ³¬11.1mmol/L»òÕßÆÏÌÑÌÇÄÍÁ¿ÊÔÑé120minʱµÄѪÌÇÖµÈÔδ»Ö¸´µ½×¢ÉäǰˮƽÔòÒÔΪDMÔìÄ£Àֳɡ£¸ÃÊÖÒÕ±ØÐè¾ÓÉרÃÅÊÖÒÕѵÁ·ÇÒÐèÅäÌ×µÄÊÖÊõ×°±¸£¬»¹ÐèÏû³ýÍâÉø͸ÒÈÏÙÏû»¯Ã¸ºÍÆäËûÒȵº¼¤ËصĻìÔÓЧӦµÄÓ°Ï죬Òò´ËÆäÆÕ±éÓ¦ÓÃÊܵ½ÏÞÖÆ[4]¡£
ʹÓûùÒòÐÞÊÎÊÖÒÕ¶ÔÌض¨DNAƬ¶Ï¾ÙÐж¨µãÇóý¡¢ÇÃÈëÒÔ¼°Ìæ»»À´ÊµÏÖ»ùÒò±í´ïµÄÉϵ÷»òϵ÷£¬´Ó¶ø¹¹½¨Ïà¹Ø»ùÒòÐ͵ÄÌÇÄò²¡¶¯ÎïÄ£×Ó¡£ÕâÀàÄ£×Ó¿ÉÒÔÎȹÌÒÅ´«£¬ÓÐÀûÓÚÑо¿ÌÇÄò²¡¼°Æä²¢·¢Ö¢µÄ·¢²¡»úÖÆ£¬²¢¿ÉÓÃÓÚÌÇÄò²¡Ò©ÎïµÄɸѡºÍÒ©ÀíҩЧÑо¿¡£
Ins2-C96YµãÍ»±äСÊó
Ñо¿·¢Ã÷ÈôСÊóÒȵºËØAÁ´ÖеĵÚÆ߸ö°±»ùËáCys96£¨TGC£©±äΪTyr£¨TAC£©£¬»áµ¼ÖÂÒȵºËØAÁ´ºÍBÁ´Ö®¼äµÄÒ»¸öÒªº¦¶þÁò¼üÎÞ·¨Ðγɣ¬´Ó¶øµ¼ÖÂСÊóproinsulin-2ÂѰ׵ĹýʧÕÛµþÕâЩ¹ýʧÕÛµþµÄÂѰ׵ĻýÀÛ×îÖջᵼÖÂÄÚÖÊÍøÓ¦¼¤ºÍÒȵº¦Âϸ°ûµòÍö[3]¡£Õâ¸öÍ»±äÊÇAkitaСÊó×Ô¾õÌÇÄò²¡µÄÔµ¹ÊÔÓÉ£¬¾Ý´ËÎÒÃǹ¹½¨ÁËIns2-C96YµãÍ»±äСÊóÄ£×Ó£¬²¢ÊӲ쵽´Ó4ÖÜÁä×îÏÈ£¬Ins2-C96YÔÓºÏ×ÓСÊó¾ÍÌåÏÖ³ö¶àʳ¡¢¶àÒû¡¢¸ßѪÌÇ¡¢ÌåÖز»ÔöµÄÏÔ×ÅÌÇÄò²¡Ö¢×´£¬ÇÒÖ¢×´Ëæ×ÅÄêËêÔöÌí¶ø¼ÓÖØ£¬ÉÏÊöÑо¿Ð§¹ûÅú×¢Ins2-C96YСÊó¿É×÷ΪIÐÍÌÇÄò²¡Ñо¿µÄ¶¯ÎïÄ£×Ó¡£
Ins2-C96YµÄÏêϸÏÈÈÝ¿ÉÒÔÒƲ½ÎÒÃÇÍùÆÚÍÆÎÄ£º
¼²²¡Ð¡ÊóÄ£×ÓϵÁÐÖ®IÐÍÌÇÄò²¡Æª£¨ÉÏ£©
ͼ6.AkitaСÊó·¢²¡»ùÀ´Ô´Àí
ÒÈÏÙÌØÒìÐÔÇóýPRLRСÊó
ÔÐÊóSTZÓÕµ¼¹¹½¨GDMÄ£×ÓµÄÄѶȽϸߣ¬Òò´ËÓÐÑо¿ÕßʵÑé¹¹½¨»ùÒòÐÞÊεÄGDMÄ£×Ó¡£2019Ä꣬NteebaJµÈ¹¹½¨ÁËPRLR-floxСÊ󣬴ßÈéËØÊÜÌ壨PRLR£©ÊÇÔÐÆÚά³ÖÌåÄÚѪÌÇÎÈ̬µÄÒªº¦·Ö×Ó£¬ÇóýPRLR»ùÒòÄܵ¼ÖÂÈÑÉïÆÚ¦Âϸ°û²»¿ÉÕý³£À©Ôö£¬ÌåÄÚÆÏÌÑÌÇÎÈ̬ÊÜËð¡£½«PRLR-floxСÊóºÍpdx1-Cre£¨ÒȵºÌØÒìÐÔCre¹¤¾ßÊ󣩽»Å䣬»ñµÃµÄÑôÐÔ×Ó´úÔÚÓÐÉíʱÄÜÀÖ³ÉÊӲ쵽GDMµÄ±íÐÍ[10]¡£
GK/IRS-1Ë«»ùÒòÇóýСÊó
IRS-1-/-СÊóÌåÏÖΪÒȵºËضԿ¹£¬µ«ÓÉÓÚ¦Âϸ°û´ú³¥ÐÔÔöÉú£¬ÒȵºËØÉø͸Ôö¶à£¬ÌÇÄÍÁ¿Õý³£¡£¦Âϸ°ûÌØÒìGK±í´ï½µµÍµÄСÊó£¬ÏÔʾÇá¶ÈÌÇÄÍÁ¿Òì³£¡£Á½ÕßÔÓ½»±¬·¢µÄGK/IRS-1Ë«»ùÒòÌÞ³ýСÊó£¬ÌåÏÖ¢òÐÍÌÇÄò²¡Ö¢×´£¬¼ÈÓÐÒȵºËضԿ¹ÓÖÓÐÌÇÄÍÁ¿Òì³£¡£
GckÇóý/Hnf4aÇóý/Abcc8ÇóýµÈÄ£×Ó
Gck¡¢Hnf4a¡¢Abcc8µÈ»ùÒòÓëÒȵº¦Âϸ°û·¢Óý¡¢¹¦Ð§»òÒȵºËØÐźÅͨ·Óйأ¬ÕâЩÓÉ»ùÒòÍ»±äµ¼ÖµÄÌÇÄò²¡Í³³ÆΪµ¥»ùÒòÌÇÄò²¡¡£ËüÃǵÄÁÙ´²Ö¢×´ÓëT2DMºÍT1DMÀàËÆ£¬³£±»ÎóÕµ¼Ö»¼Õߵò»µ½×¼È·µÄÖÎÁÆ¡£
ÆÏÌǼ¤Ã¸»ùÒò£¨Gck£©±»³ÆΪ¡°ÆÏÌÑÌǸÐÊÜÆ÷¡±£¬²»µ«ÊÇÌÇ´úлÀú³ÌÖÐÒªº¦µÄÏÞËÙø£¬ÔÚ¦Âϸ°ûÖÐËü»¹¿ÉÒÔͨ¹ý¸ÐÊÜѪÌÇˮƽµ÷ÀíÒȵºËصÄÉø͸¡£GckÍ»±ä»áµ¼ÖÂÇá¶È¿Õ¸¹ÑªÌÇÉý¸ßºÍÇá¶ÈÒȵºÉø͸¹¦Ð§Òì³£[9]¡£
Hnf4aÖ÷Òª±í´ïÓÚ¸ÎÔ࣬µ«ÔÚÒÈÏÙºÍÉöÔàÉÏÒ²Óбí´ï£¬¸Ã»ùÒò±àÂëµÄת¼Òò×Óͨ¹ý¶àÖÖ;¾¶Ó°ÏìÌÇ´úл£¬Hnf4aÍ»±ä»áµ¼Ö¸ßÒȵºËØѪ֢ºÍÖØ´ó¶ùµÄÖ¢×´[10]¡£
Abcc8»ùÒò±àÂëÔÚÒȵºËØÉø͸ÖÐÆðÖ÷Òª×÷ÓõÄKATPͨµÀµÄSUR1µ÷ÀíÑǵ¥Î»£¬ÆäÍ»±ä¿ÉÓ°Ïì¼ØÀë×ÓͨµÀ¹Ø±ÕºÍ¦Âϸ°ûĤµÄÈ¥¼«»¯¡¢ÒÖÖÆÒȵºËØÉø͸£¬µ¼Ö³£È¾É«ÌåÏÔÐÔÒÅ´«ÐÔÌÇÄò²¡[11]¡£
¹¹½¨ÉÏÊöÒªº¦»ùÒòµÄÇóýÄ£×ÓºÍÌõ¼þÐÔÇóýÄ£×Ó£¬¿ÉÓÃÓÚµ¥»ùÒòÌÇÄòµÄ»úÖÆÑо¿£¬ÊÇÌá¸ßµ¥»ùÒòÌÇÄò²¡¸öÌ廯¾«×¼ÕïÖÎˮƽµÄÒªº¦¡£
GLP-1RÈËÔ´»¯Ä£×Ó
ÒȸßѪÌÇËØÑùëÄ-1ÊÜÌ壨glucagon-like peptide-1 receptor, GLP-1R£©ÆÕ±éÂþÑÜÔÚÒȵº¡¢Î¸¡¢Ð¡³¦¡¢ÐÄÔà¡¢ÉöÔà¡¢·Î¡¢´óÄÔµÈ×éÖ¯Æ÷¹ÙÖУ¬ µ±Ëü±»GLP-1ijÈ˹¤ºÏ³ÉµÄGLP-1R¼¤¶¯¼Á¼¤»îºó£¬±ãÄÜÊ©Õ¹¶àÖÖ²î±ðµÄÐÄÀí¹¦Ð§¡£GLP-1RµÄÖ÷Òª×÷ÓÃÊǺÍÒȸßѪÌÇËØÑùëÄ-1ÍŽᣬµ÷ÀíѪÌÇ£¬ËüÊÇÖÎÁÆ2ÐÍÌÇÄò²¡×îÓÐÓõİеãÖ®Ò»[8]¡£ÈôÊÇÄÜÔÚСÊóÉÏÇÃÈëÈËÔ´µÄGLP-1R»ùÒò£¬ÈÃСÊó±í´ïÈËÔ´GLP-1R£¬¾Í¿ÉÒÔÖ±½ÓʹÓÃСÊóÀ´É¸Ñ¡ÌÇÄò²¡Ò©Î²¢ÆðÔ´ÆÊÎöºòÑ¡Ò©ÎïµÄÒ©ÀíҩЧ£¬°ÑÒ»¾Òªµ½×ÔÔ¸ÕßÉíÉϲŻªÑéÖ¤µÄһЩҩÎïÐÔÄÜÌáÇ°µ½Ð¡ÊóÉÏʵÏÖ£¬¿ÉÒÔ´ó´ó½ÚÔ¼Ò©Î↑·¢µÄ±¾Ç®ºÍʱ¼ä¡£
¹ØÓÚGLP-1RÈËÔ´»¯Ä£×ÓµÄÏêϸÏÈÈÝ¿ÉÒÔ²éÔÄÌÚ²©»á¹ÙÍøÍùÆÚÍÆÎÄ£º
GLP-1RØ2ÐÍÌÇÄò²¡ÖÎÁƵÄÃ÷Ðǰеã
ͼ7.GLP-1RµÄÐÄÀí¹¦Ð§
ÄÏÄ£ÉúÎïÓżªÊóÄ£×Ó×ÊÔ´¿âº¬¶àÖÖ×ÔÖ÷¹¹½¨µÄ»ùÒòÐÞÊÎÌÇÄò²¡Ñо¿Ä£×Ó£¬¿ÉÓÃÓÚÌÇÄò²¡µÄ»ù´¡Ñо¿ºÍÒ©Î↑·¢£¬Ïêϸģ×ÓÐÅÏ¢¼ûÏÂ±í£º
*£º¼²²¡Õ¹ÍûÊý¾ÝÊÇ»ùÓÚÒѽÒÏþÎÄÏ×ÖеĽüËÆÄ£×Ó £¨Ó빫˾ģ×Ó¾ßÓÐÏàËƵĹ¹½¨Õ½ÂÔ»ò»ùÒòÐÍ£©Õ¹Íû»ñµÃ¡£
ÄÏÄ£ÉúÎïÉî¸û»ùÒò±à¼ÁìÓò£¬Ìṩȫ·½Î»Ä£Ê½ÉúÎïЧÀÍ£¬°üÀ¨»ùÒòÐÞÊÎÖÆÆ·Ä£×Ó¹©Ó¦¡¢¸öÐÔ»¯Ä£×Ó¶¨ÖÆ¡¢ËÇÑø·±Óý¡¢±íÐÍÆÊÎö¡¢Ò©Ð§ÆÀ¼ÛµÈ£¬Öª×ã²î±ðʵÑéÊÒÐèÇó¡£
²Î¿¼ÎÄÏ×£º(ÉÏÏÂת¶¯Éó²é¸ü¶à)
[1]Öйú2ÐÍÌÇÄò²¡·ÀÖÎÖ¸ÄÏ£¨2020°æ£©
[2]KachapatiK,AdamsD,BednarK,etal.Thenon-obesediabetic(NOD)mouseasamodelofhumantype1diabetes.MethodsMolBiol.2012;933:3-16.
[3]LeMayC,ChuK,HuM,etal.Estrogensprotectpancreaticbeta-cellsfromapoptosisandpreventinsulin-deficientdiabetesmellitusinmice.ProcNatlAcadSciUSA.2006Jun13;103(24):9232-7.
[4]KleinertM,ClemmensenC,HofmannSM,etal.Animalmodelsofobesityanddiabetesmellitus.NatureReviewsEndocrinology,2018,14(3).
[5]https://www.who.int/zh/news-room/fact-sheets/detail/diabetes
[6]WuJ,YanLJ.Streptozotocin-inducedtype1diabetesinrodentsasamodelforstudyingmitochondrialmechanismsofdiabetic¦Âcellglucotoxicity.DiabetesMetabSyndrObes.2015Apr2;8:181-8.
[7]NteebaJ,KubotaK,WangW,etal.Pancreaticprolactinreceptorsignalingregulatesmaternalglucosehomeostasis.JEndocrinol.2019;241(1):71¨C83.doi:10.1530/JOE-18-0518
[8]Laviola L, Leonardini A, Melchiorre M, et al. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology, 2012, 153 : 5770¨C5781. DOI:10.1210/en.2012-1461
[9]McDonald, T. J. & Ellard, S. Maturity onset diabetes of the young: identification and diagnosis. Annals of clinical biochemistry 50,403-415,doi:10.1177/0004563213483458 (2013).
[10] Anik, A., Catli, G., Abaci, A. & Bober, E. Maturity-onset diabetes of the young (MODY): an update. Journal of pediatric endocrinology & metabolism : JPEM 28, 251-263, doi:10.1515/jpem-2014-0384 (2015).
[11]Wen, X. & Yang, Y. Emerging roles of GLIS3 in neonatal diabetes, type 1 and type 2 diabetes. Journal of molecular endocrinology 58, R73-R85, doi:10.1530/JME-16-0232 (2017).